cd19/cd22-car-transduced t cells
B-Cell Lymphoma
National Cancer Institute (NCI)Cell therapyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 73/ 100
Competitive context
17 Active assets in the B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Mwanasha Merrill, MD | Phase 3 | BB |
Venetoclax Nurix Therapeutics, Inc. | Phase 2 | B |
Clofarabine M.D. Anderson Cancer Center | Phase 2 | B |
LMB-C Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 | B |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE National Cancer Institute (NCI) | Phase 2 | CCC |
View all 40 →
Same molecule, other indications
cd19/cd22-car-transduced t cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →